Fuks_Lab retweeted
Outstanding meeting so far. So much exciting science organised by @FuksLab
#Epigenetics & #Epigenomics in Health and Disease #eehd22
@FuksLab organizer & 20+ speakers-
@berger_lab @AdelmanLab @giacomo_cavalli @David_Lab_MSK @ReinbergDanny @ludicroce @CKadoch @WhetstineLab @TKLABUK @helin_kristian @MAF_Dawson @1RabP
Fuks_Lab retweeted
MEET THE LAB!
In this case just me. During the next three days, I will be at #EEHD22 @ULBruxelles explaining how we mine the chromatin regulatory space to increase drug response.
Big thanks and kudos for organizing to Francois @FuksLab.
Fuks_Lab retweeted
Excited to see so many colleagues & friends in Brussels at the #Epigenetics & #Epigenomics in Health & Disease meeting. Thanks @FuksLab for organizing! @berger_lab kicks it off.
@David_Lab_MSK @ludicroce @MAF_Dawson @TKLABUK @FoxChaseCancer @CeiFccc
Fuks_Lab retweeted
#Epigenetics & #Epigenomics in Health and Disease #eehd22
@FuksLab organizer & 20+ speakers-
@berger_lab @AdelmanLab @giacomo_cavalli @David_Lab_MSK @ReinbergDanny @ludicroce @CKadoch @WhetstineLab @TKLABUK @helin_kristian @MAF_Dawson @1RabP
Fuks_Lab retweeted
⭐️ONLINE @NatureCancer: FTO m6A RNA demethylase regulates EMT-mediated tumor progression + sensitivity to Wnt inhibition, by @FuksLab &Co
Don't miss it!
go.nature.com/3Ae4cCq
rdcu.be/cnqhi
And the NVs by @genophoria
go.nature.com/3dtSyKe
rdcu.be/cnqhv
Fuks_Lab retweeted
#cancer : vers une nouvelle thérapie inédite contre les métastases. L'équipe de chercheurs emmenés par François Fuks vient de publier ses recherches dans @NatureCancer actus.ulb.be/fr/actus/recher…
Fuks_Lab retweeted
#Cancer I Avancée majeure sur compréhension de l’apparition des #métastases : vers un nouveau paradigme de traitement des cancers basé sur épigénétique de #ARN. Travaux de l’équipe du Prof. François Fuks, Dir. Labo Epigénétique Cancer @ULBruxelles #Télévie
actus.ulb.be/fr/actus/recher…
Fuks_Lab retweeted
Cancer : des chercheurs de l'ULB font une avancée dans la compréhension des métastases
rtbf.be/auvio/detail_medecin…















